OPA1 an Estrogen-Mediated Modulator of Platelet Hyperactivation
OPA1 是雌激素介导的血小板过度活化调节剂
基本信息
- 批准号:10614311
- 负责人:
- 金额:$ 73.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsBioenergeticsBiological ModelsBlood PlateletsCollaborationsComplementComplexContraceptive UsageCoronary ArteriosclerosisCoronary heart diseaseDataDiabetes MellitusEpidemiologyEstrogen ReplacementsEstrogensExhibitsExposure toFemaleFollow-Up StudiesGene ExpressionGonadal Steroid HormonesHemostatic AgentsHormonesHumanImpairmentIn VitroInner mitochondrial membraneIowaKnock-outKnockout MiceKnowledgeLinkMediatingMegakaryocytesMembrane ProteinsMessenger RNAMetalloproteasesMitochondriaModelingMolecularMorphologyMusOPA1 geneOptic AtrophyOral ContraceptivesOvariectomyParticipantPatientsPatternPeptide HydrolasesPhasePhenotypePhysiologicalPlatelet ActivationPlatelet aggregationPostpartum PeriodPregnancyPregnant WomenPremenopauseProteinsRecording of previous eventsRiskRoleSignal PathwaySignal TransductionSystemTestingThird Pregnancy TrimesterThrombosisTimeTranscriptTransgenic MiceUniversitiesUtahVenous ThrombosisWomanWorkZincbasecohortgenetic manipulationhuman modelhuman pluripotent stem cellhuman subjectin vivoin vivo Modelindexinginduced pluripotent stem cellinnovationmalemetabolomicsmolecular phenotypemouse modelnext generationnovelnovel markeroverexpressionpillplatelet functionplatelet phenotypepregnantprogramsrecruitresponsesexthromboticthrombotic complicationstranscriptome sequencingtranscriptomicsvenous thromboembolism
项目摘要
Strong epidemiological evidence links pre-menopausal estrogen exposure to increased risk of venous
thrombosis in women, particularly during pregnancy, in the immediate postpartum period, and in women taking
estrogen-containing oral contraceptives (OCP). This proposal addresses a significant knowledge gap linking
estrogens with platelet activation. Studies in the past have focused on how estrogens alter the hemostatic and
fibrinolytic system. This proposal, which focuses on platelets, represents a productive collaboration between
the Universities of Iowa and Utah. Our preliminary studies in the Framingham cohort and in pregnant humans,
reveal increased platelet OPA1 levels in females, that predict risk of coronary artery disease, or correlate with
increased platelet activation in the third trimester of pregnancy. In platelet-deficient OPA1 knockout (KO) mice
we discovered that female OPA1KO mice were protected from thrombosis compared to males. The
thrombosis phenotype was reversed after oophorectomy. Based on these preliminary findings, we hypothesize
that OPA1 and regulators of OPA1 activity, OMA1 and YMEL1, modulate platelet activation in an
estrogen-dependent manner and OPA1 levels in platelets predict estrogen modulated platelet
activation. To address this hypothesis in the R61 phase, Aim 1 will determine the molecular mechanisms for
estrogen-mediated and OPA-1-dependent modulation of platelet activation using mice with platelet specific
OPA1 deletion and will generate OMA1 and YMEL1 platelet specific KO mice, with increased OPA1 activity.
Aim 2 will determine platelet OPA1, OMA1, and YMEL1 expression and correlate expression levels to platelet
activation in the setting of pregnancy and OCP use. We will also develop a human iPSC model system to
generate MKs to determine if estrogen directly regulates the expression of these genes. The R33 phase will
dissect the molecular mechanisms linking increased OPA1 with platelet activation in females. Aim 1 will
perform detailed physiological and molecular phenotyping of murine platelets isolated from OMA1 and YMEL1
KO and OPA overexpressing transgenic mice. In addition, we will examine the mechanisms linking increased
OPA1 activity, mitochondrial energetics and platelet activation. Aim 2 will complement animal studies by
examining changes in mitochondrial function and signaling in platelets from pregnant women and women on
OCPs. We will genetically ablate OMA1 and YMEL1 from iPSC-derived MKs to directly test if estrogen
modulates MK and platelet function in an OPA1 dependent manner. By integrating in vivo and in vitro studies
in humans and mouse models, our approach is translational, innovative and highly responsive to the RFA.
These studies will determine for the first time whether increased estrogen exposure in pregnancy and OCP use
reprogram MKs and developing platelets to increase thrombotic complications and identify novel mechanisms
for this increased risk. The impact of these studies, is that they may identify novel biomarkers that may predict
increased risk of thrombosis in susceptible females during pregnancy or prior to OCP use.
强有力的流行病学证据将绝经前雌激素暴露与静脉炎风险增加联系起来
血栓形成的妇女,特别是在怀孕期间,在产后期间,并在妇女服用
含雌激素的口服避孕药(OCP)。本建议涉及一个重大的知识差距,
雌激素与血小板活化过去的研究集中在雌激素如何改变止血和
纤溶系统这一以血小板为重点的提案代表了以下方面富有成效的合作:
爱荷华州和犹他州的大学。我们在Fraurons队列和怀孕人类中的初步研究,
显示女性血小板OPA 1水平升高,可预测冠状动脉疾病的风险,或与
妊娠晚期血小板活化增加。在血小板缺陷型OPA 1敲除(KO)小鼠中
我们发现雌性OPA 1 KO小鼠与雄性相比免于血栓形成。的
血栓形成表型在卵巢切除术后逆转。基于这些初步发现,我们假设
OPA 1和OPA 1活性调节剂OMA 1和YMEL 1在血小板活化中调节血小板活化,
雌激素依赖性方式和血小板中OPA 1水平预测雌激素调节的血小板
activation.为了解决R61阶段的这一假设,Aim 1将确定R61阶段的分子机制。
雌激素介导的和OPA-1依赖的血小板活化调节使用血小板特异性
OPA 1缺失并将产生OMA 1和YMEL 1血小板特异性KO小鼠,具有增加的OPA 1活性。
目标2将确定血小板OPA 1、OMA 1和YMEL 1表达并将表达水平与血小板相关
在怀孕和使用OCP的情况下激活。我们还将开发人类iPSC模型系统,
产生MK以确定雌激素是否直接调节这些基因的表达。R33阶段将
剖析女性中OPA 1增加与血小板活化之间的分子机制。目标1将
对分离自OMA 1和YMEL 1的小鼠血小板进行详细的生理和分子表型分析
KO和OPA过表达转基因小鼠。此外,我们还将研究与增加的
OPA 1活性、线粒体能量学和血小板活化。Aim 2将通过以下方式补充动物研究:
检查孕妇和服用抗血小板药物的妇女的血小板中线粒体功能和信号传导的变化,
OCP我们将从iPSC衍生的MK中基因切除OMA 1和YMEL 1,以直接测试雌激素
以OPA 1依赖性方式调节MK和血小板功能。通过整合体内和体外研究
在人类和小鼠模型中,我们的方法是转化的,创新的,对RFA高度敏感。
这些研究将首次确定是否增加雌激素暴露在怀孕和口服避孕药的使用
重新编程MK和血小板发育,以增加血栓并发症,并确定新的机制
对于这种增加的风险。这些研究的影响是,他们可能会发现新的生物标志物,
在怀孕期间或使用OCP之前,易感女性血栓形成的风险增加。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
E Dale Abel其他文献
E Dale Abel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('E Dale Abel', 18)}}的其他基金
Modulating ROS by Electromagnetic Fields to Treat Type 2 Diabetes
通过电磁场调节 ROS 治疗 2 型糖尿病
- 批准号:
10570226 - 财政年份:2021
- 资助金额:
$ 73.35万 - 项目类别:
Modulating ROS by Electromagnetic Fields to Treat Type 2 Diabetes
通过电磁场调节 ROS 治疗 2 型糖尿病
- 批准号:
10393667 - 财政年份:2021
- 资助金额:
$ 73.35万 - 项目类别:
OPA1 an Estrogen-Mediated Modulator of Platelet Hyperactivation
OPA1 是雌激素介导的血小板过度活化调节剂
- 批准号:
10026343 - 财政年份:2018
- 资助金额:
$ 73.35万 - 项目类别:
Insulin Inhibition of beta-AR Signaling in the Myocardium
胰岛素对心肌 β-AR 信号传导的抑制
- 批准号:
9207133 - 财政年份:2015
- 资助金额:
$ 73.35万 - 项目类别:
Insulin Inhibition of beta-AR Signaling in the Myocardium
胰岛素对心肌 β-AR 信号传导的抑制
- 批准号:
8899989 - 财政年份:2015
- 资助金额:
$ 73.35万 - 项目类别:
Cardiac Dysfunction in the Met Syndrome: Cross-talk between IR and bAR Signaling
Met 综合征中的心脏功能障碍:IR 和 bAR 信号传导之间的串扰
- 批准号:
9272923 - 财政年份:2015
- 资助金额:
$ 73.35万 - 项目类别:
Insulin Inhibition of beta-AR Signaling in the Myocardium
胰岛素对心肌 β-AR 信号传导的抑制
- 批准号:
9036439 - 财政年份:2015
- 资助金额:
$ 73.35万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 73.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists